We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks (IC TITAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00719914
Recruitment Status : Terminated (Poor enrollment)
First Posted : July 22, 2008
Results First Posted : August 27, 2012
Last Update Posted : August 27, 2012
Information provided by (Responsible Party):
C. Michael Gibson, MS, MD, Brigham and Women's Hospital

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: ST-Elevation Myocardial Infarction
Interventions: Drug: eptifibatide
Drug: normal saline

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Additional Bolus of Eptifibatide Intracoronary injection of eptifibatide
Bolus of Normal Saline Intracoronary injection of normal saline.

Participant Flow:   Overall Study
    Additional Bolus of Eptifibatide   Bolus of Normal Saline
STARTED   10   7 
COMPLETED   10   7 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Additional Bolus of Eptifibatide Intracoronary injection of eptifibatide
Bolus of Normal Saline Intra-coronary injection of normal saline.
Total Total of all reporting groups

Baseline Measures
   Additional Bolus of Eptifibatide   Bolus of Normal Saline   Total 
Overall Participants Analyzed 
[Units: Participants]
 10   7   17 
[Units: Years]
Mean (Standard Deviation)
 57.9  (10.2)   67  (9.5)   61.6  (10.7) 
Age, Customized 
[Units: Participants]
<=18 years   0   0   0 
Between 18 and 75 years   9   6   15 
>=75 years   1   1   2 
[Units: Participants]
Female   1   0   1 
Male   9   7   16 
Region of Enrollment 
[Units: Participants]
United States   10   7   17 

  Outcome Measures

1.  Primary:   Improvement in Percent Diameter Stenosis of the Culprit Artery Following the IC Bolus Administration of Eptifibatide vs. IC Placebo (Saline) as Assessed With Quantitative Coronary Angiography (QCA)   [ Time Frame: 30 days ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Early termination due to poor enrollment.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: C. Michael Gibson, MS, MD
Organization: Brigham and Women's Hospital
phone: 617-632-7753
e-mail: mgibson@perfuse.org

Responsible Party: C. Michael Gibson, MS, MD, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT00719914     History of Changes
Other Study ID Numbers: T101
First Submitted: January 7, 2008
First Posted: July 22, 2008
Results First Submitted: July 24, 2012
Results First Posted: August 27, 2012
Last Update Posted: August 27, 2012